Olfactory impairment is an early symptom of Alzheimer’s disease (AD) and is used
as a preclinical marker in humans - but is this behavioral symptom also developed by the
transgenic AD model mouse strain Tg6799? And if it is, does it precede other behavioral symptoms and how does it correlate to neuropathologic amyloid-β plaque load?

This study was performed  during the fall of 2009 in the Shepherd lab at the department of Neurobiology, Yale University School of Medicine.

Supervisors: Matthias Laska and David Willhite